PreferredStockChannel

Slideshow Preferred Stock Offerings

By Preferred Stock Channel Staff, updated Thu, December 2, 6:13 PM

Slide #14. Viridian Therapeutics, Inc. Preferred Stock Offering

Company: Viridian Therapeutics, Inc. (NASDAQ:VRDN)
Date announced: 9/20/2021
Shares Offered: 23,126
Date of Pricing: 9/21/2021
Price Per Share: $733.37
Preferred Stock Offering Details: Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but underserved by today's therapies, today announced that it has commenced an underwritten public offering of shares of its common stock and series B preferred stock (the "Series B Preferred"). All of the securities to be sold in the underwritten public offering are being offered by Viridian. In addition, Viridian has granted the underwriters a 30-day option to purchase additional shares of its common stock. Each share of Series B Preferred will be convertible into 66.67 shares of common stock at the election of the holder, subject to beneficial ownership conversion limits applicable to the Series B Preferred. -updated 9/21- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but underserved by today's therapies, today announced the pricing of an underwritten public offering with gross proceeds of approximately $85.0 million. Viridian is selling a total of 6,185,454 shares of common stock at a public offering price of $11.00 per share and 23,126 shares of series B preferred stock (the "Series B Preferred") at a public offering price of $733.37 per share, which are convertible into approximately 1,541,810 shares of common stock, subject to beneficial ownership conversion limits. In addition, Viridian has granted the underwriters a 30-day option to purchase an additional 1,159,089 shares of common stock at the public offering price less underwriting discounts and commissions.

Viridian Therapeutics is a biotechnology company. Co. is developing multiple product candidates to treat patients who suffer from thyroid eye disease (TED), an auto-immune disease that causes inflammation and fibrosis of the orbit and tissues surrounding the eye which can lead to proptosis, or bulging of the eyes, redness and swelling, double vision, pain, and potential blindness. Co.'s primary program, VRDN-001, is a humanized monoclonal anti-insulin-like growth factor-1R (anti-IGF-1R) antibody that Co. has licensed from ImmunoGen, Inc. Co. is also developing VRDN-002, an IGF-1R monoclonal antibody, for TED.
Open the VRDN Page at Preferred Stock Channel »

Name: 
Viridian Therapeutics Inc
Website: 
www.miragentherapeutics.com
Sector: 
Biotechnology
Number of ETFs Holding VRDN: 
4 (see which ones)
Total Market Value Held by ETFs: 
$10,766,997
Total Market Capitalization: 
$418,000,000
% of Market Cap. Held by ETFs: 
2.58%
 

Open the VRDN Page at Preferred Stock Channel (in a new window) »

Quotes delayed 20 minutes

Email EnvelopeFree VRDN Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

Strong Buy (4.00 out of 4)
74th percentile
(ranked higher than approx. 74% of all stocks covered)
Based on data provided by Zacks Investment Research via Quandl.com
Top Ten Highest Yielding Preferred Stocks
Feel-Good Income: Socially Responsible Preferreds
Dividend Channel's 25 S.A.F.E. Dividend Stocks
Increasing Payments For Decades

Safer than S.A.F.E: Preferreds of Dividend Channel's
S.A.F.E. Dividend Stocks

Recent Preferred Stock Offerings
Preferred Stocks of Dow Components
Preferred Stocks of S&P 500 Components
Preferred Stocks By Industry
Preferred Stocks Where Insiders Are Buying The Common
High Yield Preferred Stocks
Preferreds Trading At Premiums To Liquidation Preference
Preferreds Trading At Discounts To Liquidation Preference
The Top 10 DividendRank'ed U.S. Stocks
The Top 10 DividendRank'ed Canadian Stocks
Top 25 Broker Analyst Picks of the S&P 500
Stock market game

Preferred Stock Offerings - Slide 14 of 573 | www.PreferredStockChannel.com

Copyright © 2010 - 2021, All Rights Reserved Nothing in Preferred Stock Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact Preferred Stock Channel; Meet Our Editorial Staff.